Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S. Dellon, Ikuo Hirano, Thai Nguyen-Cleary et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 15
S455 Efficacy and Safety of the Selective Sphingosine 1-Phosphate Receptor Modulator, Etrasimod, in Adult Patients With Eosinophilic Esophagitis: Primary Results From the Phase 2 VOYAGE StudyEvan S. Dellon, Ikuo Hirano, Margaret H. Collins et al.|The American Journal of Gastroenterology|2023Cited by 10
635 EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDYEvan S. Dellon, Ikuo Hirano, Margaret H. Collins et al.|Gastroenterology|2024Cited by 3